RBM4 Protein Found to be Decreased in Breast and Lung Cancers
the Cancer Therapy Advisor take:
According to findings published in the journal Cancer Cell, researchers have found that RNA-binding protein 4 (RBM4), a protein involved in the gene splicing process, is extremely decreased in various forms of human cancer, including lung cancers. Researchers from the University of North Carolina School of Medicine in Chapel Hill, North Carolina suggest that RMB4 could be a new genetic target for cancer drugs.
Zefeng Wang, PhD, a member of the UNC Lineberger Comprehensive Cancer Center and associate professor in the department of pharmacology, says his team's results demonstrate the RBM4 is decreased in cancer cells versus normal cells, and particularly low in breast and lung cancers. In normal cells, RBM4 makes genes splice from a long form to a short form. One gene in particular that it splices, Bcl-x, is favored in its short form due to its anti-cancer properties, but when RBM4 is low, the long form of Bcl-x, which promotes cancer growth and spread, is produced.
Furthermore, researchers found that by activating RBM4 in mice, cancer progression was reversed. The next step is to figure out what inactivates RBM4, what can target it, and how to manipulate it to treat patients with cancer.
RNA-binding protein 4 is extremely decreased in various forms of cancer, including lung cancers.
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that UNC researcher Zefeng Wang, PhD, discovered is drastically reduced in human lung and breast cancer cells.
Researchers from the UNC School of Medicine have discovered that the protein RBM4, a molecule crucial to the process of gene splicing, is drastically decreased in multiple forms of human cancer, including lung and breast cancers. The finding, published today in the journal Cancer Cell, offers a new route toward therapies that can thwart the altered genetic pathways that allow cancer cells to proliferate and spread.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models